Navigation Links
Surgeons report significant migraine relief from cosmetic eyelid surgery technique
Date:7/31/2014

New Orleans, LA Dr. Oren Tessler, Assistant Professor of Clinical Surgery at LSU Health Sciences Center New Orleans School of Medicine, is part of a team of plastic and reconstructive surgeons who report a high success rate using a method to screen and select patients for a specific surgical migraine treatment technique. More than 90% of the patients who underwent this surgery to decompress the nerves that trigger migraines experienced relief and also got a bonus cosmetic eyelid surgery. The study, which confirms the benefit of surgical treatment for migraines and expands access to it, is published online ahead of print in the journal, Plastic and Reconstructive Surgery.

The technique offers an alternative to the commonly used endoscopic approach which works down from the scalp under the skin. There are many cases that are not suitable for this approach, ranging from the patient's anatomical issues to some surgeons' lack of access to endoscopes or experience with them. The research team found that, in a select group of patients, incisions through the upper eyelid resulted in equally effective release and deactivation of the nerves involved in migraines.

The researchers, who also included surgeons from Massachusetts General Hospital and Harvard Medical School, report an overall positive response rate of 90.7%. Migraine headaches were totally eliminated in 51.3% of the patients, with about a fifth of them experiencing an 80% reduction of symptoms. Nearly a third of the patients had between 50 and 80% of their symptoms resolved.

Thirty-five patients participated in the study. All suffered from chronic nerve compression migraine headaches confirmed by previous positive response to Botox or nerve block treatments.

More than 17% of women and 5% of men in the US suffer migraine headaches. One recent study reported that the burden of headache was highest in females 18-44, where the 3-month prevalence of migraine or severe headache was 26.1
'/>"/>

Contact: Leslie Capo
lcapo@lsuhsc.edu
504-568-4806
Louisiana State University Health Sciences Center
Source:Eurekalert

Page: 1 2

Related biology news :

1. Beckers Spine Review Releases List of 50 Spine Surgeons & Specialists Researching Biologics for Spine Treatments
2. APS issues new policy requiring identification of sex or gender in reporting scientific research
3. Report presents designs for study of cancer risks near US nuclear facilities
4. Researchers report potential for a moderate New England red tide in 2012
5. Aware, Inc. Reports First Quarter 2012 Financial Results
6. Radiologists study necessity of additional imaging recommendations in PET/CT oncologic reports
7. BGI reports the completed sequence of foxtail millet genome
8. Science reporters win ASM Public Communications Award
9. ACRG and BGI report findings from genomics research on recurrent hepatitis B virus integration
10. iView Systems iTrakĀ® version 5.5 delivers optimized Incident Reporting
11. Report details efforts to improve, advance indoor microbial sampling
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2015)... NexID Biometrics LLC, whose spoof-mitigation technology boosts protection ... beginning of shipments of version 2.0 of its industry ... in Potsdam, N.Y. , is making ... here today at the Walter E. Washington Convention Center. ... boosts the accuracy rate range to 96.5 to 99.5 ...
(Date:3/23/2015)... , March 23, 2015   HOYOS Labs , ... company, today announced that the Company will demonstrate multiple ... enterprise and consumers at Connect:ID on March 23 through ... HOYOS Labs will highlight the IEEE Biometric Open Protocol ... ; and enterprise access control system. BOPS was invented ...
(Date:3/20/2015)... , Mar. 20, 2015 Research and ... the addition of the "India Sensors Market ... offering. The sensor market is projected ... 2020 Consumer electronics, automotive, industrial and ... sensors in the country. In addition, adoption of ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3
... Charles Drew University of Medicine and Science and UC ... and their parents as part of a comprehensive initiative ... Karen Cheng, CDU psychiatry and human behavior ... a $480,000 grant from the Robert Wood Johnson Foundation ...
... This release is available in Spanish . ... and gaining nutrition savvyplus physical fitness skillsare emerging from ... For example, investigators Craig A. Johnston, John P. ... upon one of their earlier studies in which many ...
... scientists in the United Kingdom and the Netherlands ... become progressively more resistant to antibiotics over the ... apparent more stringent rules on use of antibiotics ... technology that broadly improves water quality in surrounding ...
Cached Biology News:Charles Drew University, UC Irvine awarded $480,000 grant for research low birth weight infants 2Charles Drew University, UC Irvine awarded $480,000 grant for research low birth weight infants 3Kids lose pounds, gain fitness in Houston study 2
(Date:5/4/2015)... 4, 2015   Tocagen Inc. , a ... from Tocagen,s ongoing investigational studies were presented at ... American Association of Neurological Surgeons (AANS)/Congress of Neurological ... 2015, in Washington, D.C. ... meeting with FDA and continues to advance towards ...
(Date:5/4/2015)... ALISO VIEJO, Calif. , May 4, 2015 /PRNewswire/ ... to eliminate preventable hospitalizations, has teamed with the ... effect of Sentrian technology on 1,000 patients with chronic ... nearly 13 million Americans and is the nation,s third ... plan members of CareMore Health System , a ...
(Date:5/1/2015)...  Northwest Biotherapeutics (NASDAQ: NWBO ) ("NW Bio"), ... for solid tumor cancers, announced today that the Company ... a $40 million investment from Woodford investment funds in ... million in NW Bio on November 19, 2014.  On ... the Company for a further $40 million investment in ...
(Date:5/1/2015)... - BioAmber Inc. (NYSE: BIOA ), an industrial ... priced an underwritten registered offering of 3,900,000 shares of ... share, and granted the underwriters in the offering a ... shares of its common stock. The gross proceeds to ... to close on May 6, 2015, subject to customary ...
Breaking Biology Technology:Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 2Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 3Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 4Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 5CareMore, Scripps Translational Science Institute, and Sentrian Launch Landmark Study of Remote Patient Monitoring for COPD Population 2CareMore, Scripps Translational Science Institute, and Sentrian Launch Landmark Study of Remote Patient Monitoring for COPD Population 3CareMore, Scripps Translational Science Institute, and Sentrian Launch Landmark Study of Remote Patient Monitoring for COPD Population 4CareMore, Scripps Translational Science Institute, and Sentrian Launch Landmark Study of Remote Patient Monitoring for COPD Population 5NW Bio Closes On $28.5 Million Second Tranche Of Woodford $40 Million Financing 2NW Bio Closes On $28.5 Million Second Tranche Of Woodford $40 Million Financing 3BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 2BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 3
... Oct. 1 /PRNewswire-FirstCall/ - Medicago U.S.A. Inc., a ... a biotechnology company focused on developing highly effective ... and Virus-Like Particles (VLPs), today announced that company ... and U.S. Congressman David Price (D-NC), are holding ...
... Market Presence in PRC Healthcare Laboratory Market -- re> SINGAPORE and HONG KONG, Sept. 30 /PRNewswire-Asia/ -- ... ... (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we need ...
... VANCOUVER, Sept. 30 /PRNewswire-FirstCall/ - Teva Pharmaceuticals Industries Ltd. ... (NASDAQ: OGXI ) announced today the initiation ... (also known as OGX-011/TV-1011) as first line therapy for ... trial is the second of three Phase 3 trials ...
Cached Biology Technology:Medicago holds official groundbreaking ceremony for its U.S. commercial grade vaccine facility 2Medicago holds official groundbreaking ceremony for its U.S. commercial grade vaccine facility 3Techcomp to Expand Market Presence in PRC Healthcare Laboratory Market 2Techcomp to Expand Market Presence in PRC Healthcare Laboratory Market 3Techcomp to Expand Market Presence in PRC Healthcare Laboratory Market 4Techcomp to Expand Market Presence in PRC Healthcare Laboratory Market 5Techcomp to Expand Market Presence in PRC Healthcare Laboratory Market 6Techcomp to Expand Market Presence in PRC Healthcare Laboratory Market 7Techcomp to Expand Market Presence in PRC Healthcare Laboratory Market 8TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER 2TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER 3TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER 4TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER 5TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER 6
... GX-1000 3-D Shaker , ,Product Information ... of the GyroTwister GX-1000 is extremely efficient, ... general mixing as well as staining gels, ... continuously adjustable across a broad range. A ...
...
... Radiolabeled Ligands\n\nReceptor-related research has long been enabled ... ligands selected to keep pace with new ... products and services for receptor research and ... If you do not find exactly what ...
...
Biology Products: